Akari Therapeutics discloses CEO separation terms: $450K payment, RSU vesting/forfeiture

Akari Therapeutics Plc

Rachelle Jacques stepped down as President and CEO effective May 1, 2024.
Separation agreement on Aug 19, 2024 provides $450K lump sum payment contingent on merger close or by Dec 2, 2024.
Vesting of RSUs representing 276M ordinary shares; forfeiture of RSUs representing 482.25M ordinary shares.
Payment condition tied to anticipated merger with Peak Bio, Inc.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Rachelle Jacques

President and Chief Executive Officer

AKTX · Akari Therapeutics Plc

Effective: 2024-05-01
Filed: August 23, 2024, 7:59 PM ET

Rachelle Jacques stepped down as the President and Chief Executive Officer of the Company, effective May 1, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Rachelle Jacques departed as President and Chief Executive Officer at Akari Therapeutics Plc.

Action: stepped down
Role: President and Chief Executive Officer

Exact text from the filing

Rachelle Jacques stepped down as the President and Chief Executive Officer of the Company, effective May 1, 2024

View on SEC.gov

Akari Therapeutics Plc filing history →

Source: SEC EDGAR

accession 0000950170-24-100211

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.